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Introduction: Fibroblast Growth Factor 21 (FGF21) is a novel metabolic factor with effect on glucose and lipid
metabolism, and shown to be elevated in diseases related to metabolic syndrome. Due to the increasing frequency
of metabolic syndrome in the pediatric population, and as FGF21 studies in children are limited, we investigated
baseline serum levels of FGF21 in healthy children during an oral glucose tolerance test.
Methods: A total of 179 children and adolescents from the COPENHAGEN Puberty Study were included. An OGTT
with glucose and insulin measurements, a dual energy X-ray absorptiometry (DXA) scan and a clinical examination
including pubertal staging were done on all subjects. Serum levels of FGF21, adiponectin, and leptin were
determined by immunoassays at baseline.
Results: The girls had significantly higher levels of FGF21 compared with boys (155 pg/mL vs. 105 pg/mL, P = 0.04).
38 children (21%) had levels below detection limit of assay. Baseline levels of FGF21 showed positive correlation
with triglycerides, but no significant correlations were found between FGF21-concentration and body mass index
(BMI), DXA-derived fat percentage, LDL- HDL- and non-HDL cholesterol, leptin or adiponectin levels, respectively.
Neither was any correlation found between baseline FGF21-levels and the dynamic changes in glucose and insulin
levels during the OGTT.
Conclusion: FGF21 is independent of adiposity in children, and the significant metabolic effect seems to be limited
to pathological conditions associated with insulin resistance. The higher levels of triglycerides in the girls may
explain the significantly higher levels of FGF21 in girls compared with boys.
Systematic review registration: The COPENHAGEN Puberty Study was registered in ClinicalTrials.gov (identifier
NCT01411527), and approved by the local ethics committee (reference no. KF 01 282214 and KF 11 2006–2033).
Keywords: Fibroblast growth factor 21, Metabolic syndrome, Oral glucose tolerance testIntroduction
Metabolic syndrome in children is becoming more fre-
quent in the pediatric population, [1,2] and pathogenetic
and prognostic factors are sought for. Recently, a new
protein, fibroblast growth factor 21 (FGF21), has been
suggested as a factor involved in regulation of carbohy-
drate and lipid metabolism [3-5].* Correspondence: anders.juul@regionh.dk
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unless otherwise stated.FGF21 expression is induced by an increase in free
fatty acids, and is regulated by peroxisome proliferator-
activated receptor-alpha (PPAR-α) in the liver [6,7] and
PPAR-gamma (PPAR-γ) in white adipose tissue [8,9]. In
the liver, FGF21 acts as an endocrine factor, as it in-
creases energy production and utilization of energy dur-
ing prolonged fasting [10]. In white adipose tissue
FGF21 acts as an autocrine factor, as it increases glucose
uptake by up-regulating glucose transporter 1 (GLUT1)
in the cell membrane [5]. Glucose also stimulates FGF21
expression through carbohydrate response-element bind-
ing protein (ChREBP) in the liver [11,12]. In adipocytes, itl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the expression of FGF21 [11]. Compared with insulin
alone, glucose uptake into cultured adipocytes is enhanced
by co-incubation with FGF21, suggesting that the effect of
FGF21 is independent and additive to insulin. Accord-
ingly, treatment with FGF21 to ob/ob mice and FGF21
transgenic mice over-expressing the human protein re-
sulted in improved glucose clearance and insulin sensitiv-
ity during OGTT [5].
Diseases related to insulin resistance such as metabolic
syndrome and type 2 diabetes mellitus have been related
to increased levels of FGF21 [13-15]. In accordance,
serum-concentrations of FGF21 correlated negatively
with insulin sensitivity and positively with the hepatic in-
sulin resistance index, HbA1c, fasting plasma glucose
levels and two hour-plasma glucose levels after an oral
glucose tolerance test in adult subjects, suggesting a re-
lation with both hepatic and whole-body insulin resist-
ance [13]. In children, knowledge on FGF21 and insulin
resistance is limited. In a cohort study of both lean and
obese children it was indicated that FGF21 levels were
positively associated with free fatty acids, leptin and
body mass index (BMI), respectively. This study further
suggested that the increase in serum-concentrations of
FGF21 in obese children was reversible with weight
loss [16]. Giannini et al. confirmed this elevation of
FGF21 in obese youth and in addition documented




BMI (kg/m2) 18.3 (15.0-26.21)
Fat percentage (%) 18.1 (7.5-29.9)
Fasting glucose (mmol/L) 4.8 (3.9-5.9)
2-h glucose (mmol/L) 5.1 (2.8-7.3)
Fasting insulin (pmol/L) 43.0 (10.0-102.0)
Peak glucose (mmol/L) 7.0 (4.7-11.2)
Triglycerides (mmol/L) 0.6 (0.4-2.4)
HDL (mmol/L) 1.5 (0.9-2.1)
LDL (mmol/L) 2.1 (0.5-3.2)
Total cholesterol (mmol/L) 3.6 (2.4-4.6)
Non-HDL cholesterol (mmol/L) 2.0 (1.1-3.2)
Apolipoproten A1 (mmol/L) 50.6 (38.7-64.4)
Apolipoproten B (mmol/L) 2.1 (1.1-3.4)
Leptin (ng/mL) 3476.0 (1884.0-37065.0)
Adiponectin (μg/mL) 22876.5 (977.0-57085.0)
V02max (ml • kg
−1 • min−1) 46.8 (30.3-63.2)
BMI = Body mass index; HDL = High-density lipoprotein cholesterol; LDL = Low-dens
HDL-cholesterol; VO2max =Maximal oxygen uptake during a cycle ergometry test.sensitivity correlated with fatty liver and markers of
hepatic apopotosis [17].
The aim of this study was to evaluate the fasting con-
centrations of serum-FGF21 in children and adolescents
in relation to anthropometrical measurements, pubertal
stages, concentrations of lipids, leptin and adiponectin,




Subjects were recruited as part of The COPENHAGEN
Puberty Study [18,19] from primary schools in the
Copenhagen community. A total of 179 healthy Caucasian
children (114 girls) aged 8,5-16,1 years volunteered
Table 1. Sixteen children and adolescents (8 girls) were
clacified as overweight (BMI > 85th percentile for age) ac-
cording to the CDC reference. None of the children meet
the IDF crieteria for metabolic syndrome [20]. The cohort
has previously been described in details [21-23]. In brief,
all participants had pubertal stages evaluated according to
Tanners classification. Twenty-seven of the girls were
post-menarcheal. Total body fat and lean mass was evalu-
ated with a whole-body dual-energy X-ray absorptiometry
(DXA) scan using a CDR 1000/W densitometer (Holo-
gic Inc., Bedford MA) with software version 6.2. Aer-
obic fitness was evaluated by assessing maximal oxygen
















6353.0 (921-49495.0) < 0.01
27757.5 (9375.0-60190.0) 0.01
39.8 (25.1-51.0) < 0.01
ity lipoprotein cholesterol; Non- HDL-cholesterol = Total cholesterol minus
Bisgaard et al. International Journal of Pediatric Endocrinology 2014, 2014:7 Page 3 of 6
http://www.ijpeonline.com/content/2014/1/7an electronically braked cycle ergometer (Ergomedic
839: Monark, Varberg, Sweden). VO2max was measured
directly using an online pulmonary gas analyzer system
(Quark CPET; Cosmed, Rome, Italy).
Blood sampling
Venous fasting blood samples were drawn after 12 h of
fasting from the ante-cubital vein into standard vacuum
tubes and centrifuged (3000 g at 10 min) within 30 min.
Plasma was immediately stored at −20°C until analysis.
A standard two-hour oral glucose tolerance test with an
oral glucose load of 1.75 g of glucose per kilogram body-
weight (maximum 75 g glucose) was performed. Blood
samples were drawn with 30 min intervals for determin-
ation of glucose and insulin. The area under the curve
(AUC) for plasma glucose (AUCglu) and plasma insulin
(AUCins), respectively, was calculated by the trapezoidal
rule.
Analyses
Serum-FGF-21 concentrations were measured with a
commercial enzyme-linked immunosorbent assay (Bio-
Vendor Human FGF-21 ELISA, BioVendor, Brno, Czech
Republic). Determination of FGF-21 was done on previ-
ously unthawed biobanked serum samples. FGF21 was
analyzed according to the manufacturer’s instruction
and measured in duplicates. According to the manufac-
turer, the limit of detection was 7 pg/mL, but the lowest
standard was 30 pg/mL, which then in our study was set
to the limit of detection (LoD). The manufacturer re-
ported the intra-assay and inter-assay coefficients of
variability (CV) to be below 5%, respectively, and with
no cross-reactivity with human Fibroblast Growth Factor
19 or Fibroblast Growth Factor 23. Our inter-assay CV’s
for the low (mean: 137.7 pg/mL) and high (mean:
536.3 pg/mL) controls were 7.0% and 5.5%, respectively.
Plasma-concentrations of adiponectin and leptin were
measured using specific high-sensitive human enzyme
linked immunosorbent assays. The adiponectin assay
(Millipore, Human ADIPONECTIN RIA-kit, St Charles,
Mi, USA) had intra-assay and inter-assay CV’s of 4.9%
and 5.4%, respectively. Detection limits were 1 – 200 ng/
mL. The leptin assay (R&D Systems, Human Leptin Im-
munoassay, Minneapolis, Mn, USA) had intra-assay and
inter-assay CV’s of 3.4% and 1.6%, respectively, and
detection limits of 7.8 – 1000 pg/mL. Glucose, triglycer-
ides, total cholesterol, high-density lipoprotein (HDL)-
cholesterol, low-density lipoprotein (LDL)-cholesterol,
apolipoprotein A1 and B, respectively, were all analyzed
in heparin-plasma on the Modular® ANALYTICS SWA,
Modular P-system (Roche Diagnostics GmbH, Mannheim,
Germany), using the calibrator for automated systems
(CFAS) and the Roche Modular® reagents for all assays
[24]. Insulin was analyzed in (heparin-plasma) determinedby an electrochemiluminescence immunoassay (Elecsys in-
sulin reagents kit; Roche Diagnostics GmbH, Mannheim,
Germany) on the Modular® ANALYTICS SWA, Modular
E170-system (Roche Diagnostics GmbH, Mannheim,
Germany) [21]. Non-HDL-cholesterol was calculated as
total cholesterol subtracted HDL-cholesterol.
Statistics
All FGF21 values below the lowest standard (30 pg/mL)
were set at 15 pg/mL. Mann–Whitney U-test was used
to evaluate differences in FGF21 and metabolic parame-
ters between genders. Differences in median levels of
FGF21 in different age groups (2-yrs intervals) and pu-
bertal stages were evaluated with Kruskal-Wallis test. To
account for samples below detection, sex-specific tertiles
of increasing FGF21 levels were generated. Differences
between several groups were evaluated with the Kruskal-
Wallis test, and differences between two groups (single
or combined) were evaluated by the Mann–Whitney U-
test. All statistical analyses were done using the statis-
tical software IBM SPSS version 19.0 for Microsoft
Windows XP (Chicago, IL).
Ethics
The study was done in accordance with the ethical princi-
ples of the Helsinki II declaration. The COPENHAGEN
Puberty Study was registered in ClinicalTrials.gov (identi-
fier NCT01411527), and approved by the local ethics
committee (reference no. KF 01 282214 and KF 11 2006–
2033). All children and parents gave their informed writ-
ten consent.
Results
In total, 38 study participants (16 boys, 22 girls) had
FGF21 levels below the lowest standard of 30 pg/mL.
The serum concentrations of FGF21 in samples above
this LoD ranged from 60.6 – 1715.1 pg/mL. As shown in
Figure 1, the girls had significantly higher serum-levels
of FGF21 (median: 155.1 pg/mL, range < LoD - 1715.1 pg/
mL) compared with the boys (median: 105.1 pg/mL,
range < LoD - 818.9 pg/mL, P = 0.04). No significant dif-
ferences were found in serum FGF21 levels between age-
groups and pubertal stages in boys and girls, respectively.
Neither did we find any association between baseline
levels of FGF21 and glucose and insulin levels during the
OGTT. Due to lack of statistical significant differences in
all measured parameters between the middle and highest
tertiles, these two groups were combined and compared
with the lowest tertile. The lowest tertile of serum FGF21
had significantly lower triglyceride (TG) levels (median:
0.61 mmol/L, range: 0.42 – 1.77 mmol/L) compared with
the combined higher tertiles (median: 0.72 mmol/L, range:
0.35 – 2.38 mmol/L, P = 0.01).
Figure 1 Serum concentration of Fibroblast Growth Factor 21
(FGF21) in a group of 179 healthy, non-obese children (114 girls,
65 boys). Each square represents the FGF21-serum concentration in
a child. In 16 boys and 22 girls the FGF21-concentration was below
the lowest standard of the assay; these values were set at 15 pg/mL.
The solid vertical lines indicate the median values of serum-FGF21 in
girls and boys, respectively. The dotted lines indicate the lowest
standard of the assay. Note that the Y-axis is logarithmic.
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in the lowest FGF21-tertile (median: 0.70 mmol/L,
range: 0.42 – 1.77 mmol/L) compared with the higher
FGF21-tertiles (median: 0.82 mmol/l, range: 0.35 –
2.03 mmol/L), P = 0.03). Similar absolute differences
were found for TG levels in boys between the lowest ter-
tile (median: 0.55 mmol/L, range 0.43 – 1.41 mmol/L)
and the higher tertiles of serum FGF21 (median:
0.65 mmol/L, range: 0.37 – 2.38 mmol/L), P = 0.11). In
addition, LDL-cholesterol levels were lower in the lowest
FGF21-tertile compared with the higher tertiles in girls
only (P = 0.07).
No differences in height, weight, BMI, total body fat
percentage (all p > 0.12) between the lowest FGF-21 ter-
tile compared with the higher tertiles for girls and boys,
respectively.
When the group of sixteen children and adolescents
with BMI above the 85th percentile for age were com-
pared to the large group of normal-weight children theyonly showed significant difference in BMI, total fat per-
centage, fasting insulin and leptin (p < 0.01) but no dif-
ference was found with either triglycerides, lipids,
cholesterol or FGF21. These findings were consistent in
a gender-specific analysis.
Discussion
In the present study, we did not find consistent evidence
in favor for a regulatory function of baseline FGF21-
concentrations on glucose homeostasis. This may reflect
the narrow biological range in the present sample of
healthy children with normal glucose tolerance. In accord-
ance, Gälman et al. found no evidence for a relationship
between FGF21 levels and metabolic parameters in
healthy adult subjects, [10] indicating that significant
metabolic effects of FGF21 may be limited to pathological
conditions associated with glucose intolerance. In
addition, as FGF21 levels were only evaluated at baseline,
dynamic changes in FGF21 levels during an OGTT could
not be determined in the present study. One study re-
ported that changes of FGF21 concentrations were nega-
tively correlated with changes of glucose levels during a
standard OGTT in both healthy and insulin resistant indi-
viduals [25].
Despite the lack of association with DXA-derived total
body adiposity, we found positive correlations between
serum-concentrations of FGF21 and triglycerides. This is
consistent with the study by Tyynismaa et al. [26]
reporting that high FGF21-levels were related to higher
proportions of liver fat and higher triglycerides levels ra-
ther than to total body adiposity. Due to the cross-
sectional design in the present study, the cause and
effect-relationship could not be determined. However,
evidence suggests that FGF21 increases in response to
increasing levels of lipids, which has been hypothesized
as a defense mechanism against lipotoxicity [3]. Thus,
FGF21 may be a marker of elevated levels of lipids even
in healthy normal-weight children. In accordance with
the lack of association between FGF21 and anthropo-
metric and biochemical parameters associated with
obesity, we found no correlation between FGF21 and the
adipokines leptin and adiponectin [27,28].
FGF21 levels were significantly higher in girls com-
pared with boys, which may partly be related to the
higher triglyceride levels in girls. No previous studies
have addressed the possible sexual differences in FGF21-
concentrations in either adults or children.
A higher number of girls are represented in the
present study, which might explain why a significant dif-
ference between the metabolic parameters and FGF21
levels is seen in girls only.
The strength of our study is the large unselected sam-
ple of 179 well-characterized children. However, experi-
mental and clinical data suggest that a certain amount of
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exert a significant glucose lowering effect [29]. Thus,
evaluation of FGF21 levels in children with obesity and
glucose intolerance may shed further light on the pos-
sible regulatory actions of FGF21.
Conclusion
Fasting concentrations of FGF21 were significantly posi-
tive associated with levels of triglycerides in girls inde-
pendently of adiposity and serum leptin levels. Baseline
FGF21 concentrations were not associated with glucose
or insulin concentrations during a two-hour OGTT. The
girls showed significantly higher levels of FGF21, which
may partly be explained by higher triglyceride concen-
trations in girls compared with boys.
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